Journey Medical Corp (DERM) SEC filings

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value

$4.33−0.06 (-1.37%)

Close on Nov 13, 2026Market cap $122.21MP/E –Yield –

SEC filings

40 of Journey Medical's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jun 24, 2026	Jun 26, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 24, 2026	Apr 30, 2026	SEC EDGAR
Current report	8-K	Apr 21, 2026	Apr 21, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 26, 2026	SEC EDGAR
Current report	8-K	Mar 25, 2026	Mar 25, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Sep 25, 2025	Sep 26, 2025	SEC EDGAR
Current report	8-K	Aug 28, 2025	Aug 28, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jul 14, 2025	Jul 14, 2025	SEC EDGAR
Current report	8-K	Jun 24, 2025	Jun 26, 2025	SEC EDGAR
Current report	8-K	Jun 24, 2025	Jun 24, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 15, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 24, 2025	Apr 29, 2025	SEC EDGAR
Current report	8-K	Apr 1, 2025	Apr 3, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 27, 2025	SEC EDGAR
Current report	8-K	Mar 26, 2025	Mar 26, 2025	SEC EDGAR
Current report	8-K	Mar 24, 2025	Mar 24, 2025	SEC EDGAR
Current report	8-K	Feb 5, 2025	Feb 5, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Nov 4, 2024	Nov 4, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 13, 2024	SEC EDGAR
Current report	8-K	Aug 12, 2024	Aug 12, 2024	SEC EDGAR
Current report	8-K	Jul 9, 2024	Jul 12, 2024	SEC EDGAR
Current report	8-K	Jun 25, 2024	Jun 25, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 14, 2024	SEC EDGAR
Current report	8-K	May 13, 2024	May 13, 2024	SEC EDGAR
Current report	8-K	Apr 26, 2024	May 1, 2024	SEC EDGAR
Proxy statement	DEF 14A	Jun 25, 2024	Apr 29, 2024	SEC EDGAR
Annual report	10-K	Dec 31, 2023	Mar 29, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Journey Medical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DERM.

Compare: DERM vs FBIO · DERM vs BFRI · DERM vs AYTU · DERM vs VRCA · DERM vs RMTI

Revenue growth17.0% · median -4.0%

Gross margin65.9% · median 64.0%

Operating margin-2.9% · median -14.4%

Net margin-7.3% · median -12.7%

Company	Revenue	Growth
RMTI	$72.58M	-4.0%
FBIO	$69.99M	+12.3%
DERM	$69.52M	+17.0%
AYTU	$57.57M	-13.3%
BFRI	$48.26M	+29.8%
VRCA	$22.89M	-25.7%

Company

Next earnings (est.): Mar 24, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 58
Held by institutions: 37.8%
Auditor: KPMG LLP
SEC CIK: 1867066

Advertisement
300 × 250

See a number that looks wrong?